Back to Search
Nylia 1/35
by Aurobindo Pharma LimitedContraceptionCOCP
Actively PrescribedGeneric

Estrogen

Ethinyl Estradiol

0.035Mg

Progestin

Norethindrone

1Mg

Regimen Protocol

Monophasic 28 day

Androgenicity

Moderate

Approval Date

10/21/2016

Additives
None
Inactive Ingredients
anhydrous lactoselactose monohydratepregelatinized starch (maize)FD&C Yellow #6 Aluminum Lakemagnesium stearatecroscarmellose sodiumFD&C Blue No. 2 Aluminum Lakeferric oxide yellowmicrocrystalline cellulosepovidone

Contains common allergens

Active Alternative Brands
Alternative brands with the same formulation that are actively prescribed

Glenmark Pharmaceuticals Inc., USA

Alyacen 1/35

Northstar Rx LLC

Dasetta 1/35

Naari Pte Ltd

Norethindrone And Ethinyl Estradiol

Watson Laboratories Inc An Indirect Wholly Owned Sub Of Teva Pharmaceuticals Usa Inc

Norethindrone And Ethinyl Estradiol

Barr Laboratories Inc

Nortrel 1/35-21

Barr Laboratories Llc (An Indirect Wholly Owned Sub Of Teva Pharmaceuticals Usa Inc)

Nortrel 1/35-28

Have clinical questions about Nylia 1/35?

Get evidence-based, cited answers from our AI co-pilot for hormone health.

Try Dama Assist

© 2026 Dama Health. All rights reserved.

This tool is intended for use by licensed healthcare professionals. It provides reference information on FDA-approved contraception and hormone therapy products. Results should not be used as a substitute for clinical judgment. Data is sourced from the FDA Orange Book and other FDA-sourced resources and may contain errors or omissions.

Last updated: July 2025 | Powered by Dama Health | Terms of Use | Privacy Policy